Novo Nordisk's experimental weight loss pill has some concerning side effects
Ozempic maker Novo Nordisk (NVO) announced mixed results today for a phase 2 trial of an experimental weight loss pill that ...
Medpage Today on MSN20d
Drug-Coated Balloon Flops for De Novo Coronary Lesions
Drug-coated balloon (DCB) angioplasty as the initial strategy for de novo coronary artery stenoses didn't measure up to ...
WHBL1d
Novo Nordisk shares drop nearly 5% on disappointing obesity pill data
By Maggie Fick and Jacob Gronholt-Pedersen LONDON/COPENHAGEN (Reuters) -Novo Nordisk's shares fell nearly 5% on Friday after ...
Medscape12d
Study: Balloon Angioplasty Plus Medical Management for sICAS
Balloon angioplasty plus medical management offered better outcomes in patients with symptomatic intracranial atherosclerotic ...
The EMBO Journal2d
Astrocyte allocation during brain development is controlled by Tcf4-mediated fate restriction
Astrocytes in the brain exhibit significant regional diversity, but the mechanisms controlling their heterogeneity remain ...
The EMBO Journal12d
Gene therapy for epilepsy targeting neuropeptide Y and its Y2 receptor to dentate gyrus granule cells
Co-expressing NPY and its inhibitory receptor Y2 in excitatory hippocampal cells allows inhibitory autoregulation of ...
eLife10d
CUTS RNA Biosensor for the Real-Time Detection of TDP-43 Loss-of-Function
CUTS is a cryptic exon RNA biosensor enabling real-time detection of TDP-43 loss of splicing function. CUTS exhibits a significant linear relationship with TDP-43 loss. CUTS can deliver an ...